SNP 119
Alternative Names: SNP-119Latest Information Update: 28 Dec 2022
At a glance
- Originator Snap Bio
- Class Antineoplastics
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 23 Nov 2018 Snap Bio plans the IND-enabling preclinical trials for Cancer in 2020 (Snap Bio website, November 2018)
- 15 Nov 2018 Snap Bio entered into a agreement with ChemDiv and Torrey Pines Investment to develop selective kinase inhibitors for endodermal cancers and autoimmune diseases